Benzinga
Vaxxinity Inc (NASDAQ: VAXX) unveiled results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson's disease (PD). UB-312 is a synthetic peptide vaccine targeting aggregated forms of aSyn, which plays a central role in PD development and progression. UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the trial's primary objectives. 92% of patients (12 out of 13) who completed dosing
Benzinga